Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18279Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Papadopoulou, S. | en |
| dc.contributor.author | Scorilas, A. | en |
| dc.contributor.author | Yotis, J. | en |
| dc.contributor.author | Arnogianaki, N. | en |
| dc.contributor.author | Plataniotis, G. | en |
| dc.contributor.author | Agnanti, N. | en |
| dc.contributor.author | Talieri, M. | en |
| dc.date.accessioned | 2015-11-24T18:51:35Z | - |
| dc.date.available | 2015-11-24T18:51:35Z | - |
| dc.identifier.issn | 1010-4283 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18279 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Carcinoma/*enzymology | en |
| dc.subject | Colon/enzymology | en |
| dc.subject | Colorectal Neoplasms/*enzymology | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Immunohistochemistry | en |
| dc.subject | Middle Aged | en |
| dc.subject | Plasminogen Activator Inhibitor 1/*metabolism | en |
| dc.subject | Urokinase-Type Plasminogen Activator/*metabolism | en |
| dc.title | Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/12218297 | - |
| heal.identifier.secondary | http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000064033 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2002 | - |
| heal.abstract | Despite the advances in the medical care of colorectal carcinoma patients, the prognosis has improved only marginally over recent decades. Thus, additional prognostic indicators would be of great clinical value to select patients for adjuvant therapy. In the present study, the antigen levels of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1, and their immunohistochemical staining were compared in paired colorectal tumor (n = 64) and background colon tissue of the same patients with clinical and pathological staging. The antigen levels, measured with an ELISA method, were found to be significantly higher in cancer tissue (mean 1.92 ng/mg protein for uPA and 7.08 for PAI-1) than in corresponding normal mucosa (0.29 ng/mg protein for uPA and 1.11 ng/mg protein for PAI-1). There was a positive correlation between uPA and PAI-1 antigen levels and clinicopathological parameters such as grade (p < 0.001 and p = 0.01, respectively), while for Dukes' stage, only PAI-1 correlated positively (p = 0.018). Nodal status correlated positively with uPA but not with PAI-1 antigen levels. Immunohistochemical localization of both antigens was observed mainly in cancer cells and much less in stromal cells. Staining intensity increased from adenoma to adenocarcinoma. The degree of staining was associated with grade, Dukes' stage and nodal status for uPA (p < 0.001, p = 0.002, p < 0.001, respectively) and only with grade for PAI-1 (p = 0.007). | en |
| heal.journalName | Tumour Biol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
